ClinicalTrials.gg
RecruitingNCT00900419Updated Nov 3, 2026

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

An observational study in Esophageal Cancer, Head and Neck Cancer and Lung Cancer, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Colorado, Denver · Observational

How we know

From the registry’s dates

  • Started May 2001; still recruiting 25 years 6 months later.
Updated Nov 3, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
700
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 676 studies in Esophageal Neoplasms with a site in United States — 122 open to participants now, 171 under way, 2 of them phase 3. Esophageal Neoplasms · United States.

Planned enrollment
32nd of 112
700 · median 152
Started
2001
with 19 others
Observational
112 of 676
34 open now
Primary completion
2028-10
later than 126 of 169 live
Registered
239th of 676
by date

Among the 676 studies in Esophageal Neoplasms with a site in United States, this one is the 32nd largest by planned enrollment of the 112 observational ones that give a count, is one of 20 that started in 2001, is one of 112 observational ones, reaches primary completion later than 126 of the 169 other live ones, and was the 239th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

122 of the 676 studies in Esophageal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 21 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 676 studies in Esophageal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future.

PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.

Read the detailed description

OBJECTIVES:

Primary

  • Determine intermediate biomarkers of premalignant respiratory epithelial lesions, such as genetic mutations or altered growth factor expression, in patients with dysplasia of the respiratory epithelium or lung cancer, head and neck cancer, or aerodigestive tract cancer.

Secondary

  • Establish a tissue repository of normal and dysplastic respiratory epithelium from endobronchial forceps and brush biopsy tissue from these patients and from normal volunteers.

OUTLINE: Patients are stratified according to presence of extensive and severe dysplasia of the respiratory epithelium (yes vs no).

Participants undergo sputum cytology, white-light (with or without fluorescence) bronchoscopy, and endobronchial biopsies. Participants also undergo endobronchial brushings and bronchial secretion collection and possibly bronchoalveolar lavage. Collected samples are processed by hematoxylin, eosin, and immunohistochemical staining and analyzed for specific biomarkers. Unused samples are stored in the tissue bank.

PROJECTED ACCRUAL: A total of 330 participants will be accrued for this study.

03

Conditions studied

  • Esophageal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Precancerous Condition

Keywords

  • non-small cell lung cancer
  • small cell lung cancer
  • squamous lung dysplasia
  • hypopharyngeal cancer
  • laryngeal cancer
  • lip and oral cavity cancer
  • metastatic squamous neck cancer with occult primary
  • nasopharyngeal cancer
  • oropharyngeal cancer
  • paranasal sinus and nasal cavity cancer
  • salivary gland cancer
  • esophageal cancer
  • pulmonary carcinoid tumor
  • tongue cancer
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

High Risk for Lung Cancer, suspected lung cancer, lung cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Two broad patient groups are of interest: those with extensive and severe dysplasia of the respiratory epithelium and those without dysplasia of the respiratory epithelium. The patients with dysplasia will be recruited from the following:

  • Individuals identified through the SPORE Tissue Procurement Screening Project with moderate or severe dysplasia.
  • Patients identified by private and academic physicians with moderate or severe dysplasia on cytology.
  • One year or greater survivors of one or more aerodigestive system carcinomas.
  • Patients with head and neck cancers who are undergoing routine panendoscopy.
  • Patients undergoing resection of a bronchogenic carcinoma.
  • Fully resected Stage I non-small cell cancer patients.
  • Patient's undergoing bronchoscopy for diagnosis or staging of suspected lung cancer.
  • Subjects with previous high-grade dysplasia or worse undergoing subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment.
  • Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.
  • Patients without dysplasia will be: patients undergoing clinically indicated bronchoscopy for conditions other than suspected lung cancer.

Exclusion criteria

Exclusion Criteria:

Patients are not eligible if any one of the following conditions exist:

  • Clinically apparent bleeding diathesis.
  • Cardiac dysrhythmia that is potentially life threatening, such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well-controlled atrial fibrillation or rare (\< 2/minute) premature ventricular contractions are not exclusionary.
  • Hypoxemia (less than 90% saturation with supplemental oxygen) prior to bronchoscopy.
  • Evidence of clinically active coronary artery disease, including myocardial infarction within 6 weeks, anginal chest pain, or poorly controlled congestive heart failure, or any other serious medical condition which would preclude a patient from undergoing a bronchoscopy.
  • Acute bronchitis or pneumonia within 8 weeks, except if these are considered clinically to be possibly a result of lung cancer.
  • Inability to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Otherimmunohistochemistry staining method

    Laboratory test

  • Otherlaboratory biomarker analysis

    Laboratory Test

  • Othersputum cytology

    Laboratory Test

  • Procedurebiopsy

    Laboratory Test

06

What researchers measure

Primary outcomes

  1. Genetic mutations or altered growth factor expression

    Time frame: After study has completed

Secondary outcomes

  1. Establishment of a tissue repository of normal and dysplastic respiratory epithelium

    Time frame: After study has closed

07

Study locations

1 of 1 sites recruiting
  • University of Colorado Cancer Center at UC Health Sciences Center
    Aurora, Colorado 80045, United States
    Recruiting
    • Clinical Trials Office - University of Colorado Cancer Center · Contact303-724-1657
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2001 (actual). Primary completion is estimated for Oct 2028, 329 months after the start.

Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 329 months is above that.

Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Sep 2027 → Oct 2028 and completion Sep 2027 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2009
First posted
May 12, 2009
StartActual
May 3, 2001
Primary completionEst.
Oct 30, 2028was Sep 2027
CompletionEst.
Oct 30, 2028was Sep 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2027→Oct 30, 2028
Nov 3, 2026
Study completion
Sep 30, 2027→Oct 30, 2028
Nov 3, 2026
Eligibility
6 inclusion criteria edited, 4 added; 3 exclusion criteria edited, 4 added; 21 criteria removed
What changed in the criteria
  • RemovedInclusion Criteria:
  • RemovedDiagnosis of extensive and severe dysplasia of the respiratory epithelium
  • RemovedThose without dysplasia of the respiratory epithelium
  • RemovedSurvived 1 or more aerodigestive system carcinoma for ≥ 1 year
  • RemovedUndergoing any of the following procedures:
  • RemovedRoutine panendoscopy for patients with head and neck cancer
  • RemovedNo asthma
  • RemovedNo lung disease
  • RemovedPATIENT CHARACTERISTICS:
  • RemovedNo known bleeding disorder
  • RemovedNo anginal
  • RemovedNo clinically active coronary artery disease
  • RemovedNo multifocal premature ventricular contractions
  • RemovedNo poorly controlled congestive heart failure
  • RemovedNo myocardial infarction within the past 6 weeks
  • RemovedNo cardiac dysrhythmia that is potentially life threatening
  • RemovedWell-controlled atrial fibrillation or rare (< 2/min) premature ventricular contractions allowed
  • RemovedNo ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response
  • RemovedNo other serious medical condition that would preclude a patient from undergoing a bronchoscopy
  • RemovedPRIOR CONCURRENT THERAPY:
  • RemovedSee Disease Characteristics
Inclusion criteria
  • AddedTwo broad patient groups are of interest: those with extensive and severe dysplasia of the respiratory epithelium and those without dysplasia of the respiratory epithelium. The patients with dysplasia will be recruited from the following:
  • EditedRecruited fromIndividuals identified through the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia).
  • AddedPatients identified by private and academic physicians with moderate or severe dysplasia on cytology.
  • AddedOne year or greater survivors of one or more aerodigestive system carcinomas.
  • AddedPatients with head and neck cancers who are undergoing routine panendoscopy.
  • EditedResectionPatients undergoing resection of a bronchogenic carcinoma.
  • EditedCompletelyFully resected stageStage I non-small cell cancer patients.
  • EditedBronchoscopyPatient's undergoing bronchoscopy for diagnosis or staging of suspected lung cancer.
  • EditedSubsequentSubjects with previous high-grade dysplasia or worse undergoing subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse.
  • EditedNo respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.
Exclusion criteria
  • AddedPatients are not eligible if any one of the following conditions exist:
  • EditedNo clinicallyClinically apparent bleeding diathesis.
  • AddedCardiac dysrhythmia that is potentially life threatening, such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well-controlled atrial fibrillation or rare (< 2/minute) premature ventricular contractions are not exclusionary.
  • EditedNo hypoxemiaHypoxemia (i.e., <less than 90% saturation with supplemental oxygen) beforeprior to bronchoscopy.
  • AddedEvidence of clinically active coronary artery disease, including myocardial infarction within 6 weeks, anginal chest pain, or poorly controlled congestive heart failure, or any other serious medical condition which would preclude a patient from undergoing a bronchoscopy.
  • EditedNo acuteAcute bronchitis or pneumonia within the past 8 weeks, except whenif these are considered clinically proven asto be possibly a possible result of lung cancer.
  • AddedInability to give informed consent
Nov 3, 2026
Contact
Study contact changed: b•••@cuanschutz.edu · •••1657→b•••@cuanschutz.edu · •••1657. See the current contact
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Sep 30, 2027→Oct 30, 2028
    Study completion Sep 30, 2027→Oct 30, 2028
    Eligibility 6 inclusion criteria edited, 4 added; 3 exclusion criteria edited, 4 added; 21 criteria removed
    What changed in the criteria
    • RemovedInclusion Criteria:
    • RemovedDiagnosis of extensive and severe dysplasia of the respiratory epithelium
    • RemovedThose without dysplasia of the respiratory epithelium
    • RemovedSurvived 1 or more aerodigestive system carcinoma for ≥ 1 year
    • RemovedUndergoing any of the following procedures:
    • RemovedRoutine panendoscopy for patients with head and neck cancer
    • RemovedNo asthma
    • RemovedNo lung disease
    • RemovedPATIENT CHARACTERISTICS:
    • RemovedNo known bleeding disorder
    • RemovedNo anginal
    • RemovedNo clinically active coronary artery disease
    • RemovedNo multifocal premature ventricular contractions
    • RemovedNo poorly controlled congestive heart failure
    • RemovedNo myocardial infarction within the past 6 weeks
    • RemovedNo cardiac dysrhythmia that is potentially life threatening
    • RemovedWell-controlled atrial fibrillation or rare (< 2/min) premature ventricular contractions allowed
    • RemovedNo ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response
    • RemovedNo other serious medical condition that would preclude a patient from undergoing a bronchoscopy
    • RemovedPRIOR CONCURRENT THERAPY:
    • RemovedSee Disease Characteristics
    Inclusion criteria
    • AddedTwo broad patient groups are of interest: those with extensive and severe dysplasia of the respiratory epithelium and those without dysplasia of the respiratory epithelium. The patients with dysplasia will be recruited from the following:
    • EditedRecruited fromIndividuals identified through the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia).
    • AddedPatients identified by private and academic physicians with moderate or severe dysplasia on cytology.
    • AddedOne year or greater survivors of one or more aerodigestive system carcinomas.
    • AddedPatients with head and neck cancers who are undergoing routine panendoscopy.
    • EditedResectionPatients undergoing resection of a bronchogenic carcinoma.
    • EditedCompletelyFully resected stageStage I non-small cell cancer patients.
    • EditedBronchoscopyPatient's undergoing bronchoscopy for diagnosis or staging of suspected lung cancer.
    • EditedSubsequentSubjects with previous high-grade dysplasia or worse undergoing subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse.
    • EditedNo respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.
    Exclusion criteria
    • AddedPatients are not eligible if any one of the following conditions exist:
    • EditedNo clinicallyClinically apparent bleeding diathesis.
    • AddedCardiac dysrhythmia that is potentially life threatening, such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well-controlled atrial fibrillation or rare (< 2/minute) premature ventricular contractions are not exclusionary.
    • EditedNo hypoxemiaHypoxemia (i.e., <less than 90% saturation with supplemental oxygen) beforeprior to bronchoscopy.
    • AddedEvidence of clinically active coronary artery disease, including myocardial infarction within 6 weeks, anginal chest pain, or poorly controlled congestive heart failure, or any other serious medical condition which would preclude a patient from undergoing a bronchoscopy.
    • EditedNo acuteAcute bronchitis or pneumonia within the past 8 weeks, except whenif these are considered clinically proven asto be possibly a possible result of lung cancer.
    • AddedInability to give informed consent
    Contact Study contact changed: b•••@cuanschutz.edu · •••1657→b•••@cuanschutz.edu · •••1657. See the current contact
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00900419
Responsible party
Sponsor
First posted
May 12, 2009
Start date
May 3, 2001
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Brandi Kubala, MA, CCRP
Contact
brandi.kubala@cuanschutz.edu
303-724-1657
Robert L. Keith, MD
principal investigator · University of Colorado Cancer Center, Anschutz Medical Campus; Rocky Mountain Regional VA Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion